Discovery of gene mutation could lead to blood glucose therapy
02 May 2008

A team of British, French and Canadian researchers have discovered that a mutation in a gene known as G6PC2 or IGRP can raise the amount of glucose in a person's blood to harmful levels - and increase the risk of cardiovascular disease and early death.

The study explains that even in healthy people who do not have diabetes, high levels of blood glucose increase the risk of cardiovascular disease and early death.

Epidemiological studies have shown that 80 per cent of the risk of cardiovascular disease is related to a blood glucose level just above the average. In addition, high blood glucose levels are linked to obesity, poor nutrition and lack of exercise.

Now researchers from Imperial College London, the French National Research Institute and McGill University in Canada found an association between high levels of blood glucose and a mutation in the IGRP gene.

The mutated IGRP gene was found to block the action of a sensor called glucokinase.

Glucokinase is crucial to maintaining blood gloucose levels by signalling to cells known as beta cells which then secrete insulin to keep blood glucose levels under control.

Following the discovery, it is now hoped that a therapy will be developed to stop the defective IGRP gene from blocking the glucokinase sensor.

Professor Philippe Froguel, leading author of the research from the French National Research Institute and the Department of Genomic Medicine at Imperial College London, said: "Having a high level of blood glucose is a bit like having high cholesterol or high blood pressure in that the higher the level, the greater your risk of serious health problems. Our study helps unravel the genetic reasons why some people have higher levels of glucose in their blood than others."

The study compared the genetic makeup of 654 non-diabetic people with differing levels of blood glucose from the low to the high end of the 'normal' range; the discovery of gene mutations in these individuals was then confirmed by analysing the genetic makeup of a further 8,000 individuals with blood glucose levels within the non-diabetic range.

Click here for EPG Online physician’s tools including disease awareness, diagnosis tools, treatment options and management guidance.

Print Article    Bookmark

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...